Status:
UNKNOWN
Expression of Programmed Death-1 (PD-1) & Programmed Death Ligand-1 (PDL-1) in Acute Lymphoblastic Leukemia in Pediatric
Lead Sponsor:
Sohag University
Conditions:
Acute Lymphoblastic Leukemia in Pediatric
Eligibility:
All Genders
1-18 years
Phase:
NA
Brief Summary
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy in the world. It is a malignant clonal proliferation of lymphoid progenitor cells, but most commonly of the B cell lineage (...
Eligibility Criteria
Inclusion
- Age range from 1 day to 18 years old
- Patients who are newly diagnosed and under treatment of acute lymphoblastic leukemia
Exclusion
- Other types of acute leukemia rather than acute lymphoblastic leukemia
Key Trial Info
Start Date :
August 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05428111
Start Date
August 1 2022
End Date
August 1 2023
Last Update
June 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sohag University Hospital
Sohag, Egypt